| Type of support |
Approvals 2001-2023 (US$)(23 May 2019) |
Commitments 2001-2023 (US$)(23 May 2019) |
Disbursements 2000-2019 (US$)(23 May 2019) |
% Disbursed(23 May 2019) |
2001 |
2002 |
2003 |
2004 |
2005 |
2006 |
2007 |
2008 |
2009 |
2010 |
2011 |
2012 |
2013 |
2014 |
2015 |
2016 |
2017 |
2018 |
2019 |
2020 |
2021 |
|---|
|
| Total |
$227,633,829 |
$247,623,829 |
$227,602,367 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cash Support (CASHSUPP) |
$145,000 |
$170,000 |
$145,000 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cold Chain Equipment Optimisation Platform (CCEOP) |
$3,802,899 |
$3,802,899 |
$3,433,748 |
90% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Health system strengthening (HSS 1) |
$4,978,500 |
$4,978,500 |
$4,978,500 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Health system strengthening (HSS 2) |
$4,436,347 |
$4,436,347 |
$4,436,347 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Health system strengthening (HSS 3) |
$5,040,000 |
$11,760,000 |
$3,698,158 |
73% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| HPV Demo (NVS) |
$189,506 |
$189,506 |
$190,622 |
101% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Immunisation services support (ISS) |
$9,705,605 |
$9,705,605 |
$9,705,605 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Injection Safety Devices (NVS) |
$995,700 |
$1,288,200 |
$977,949 |
98% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Injection safety support (INS) |
$931,560 |
$931,560 |
$931,560 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| IPV (NVS) |
$2,712,179 |
$2,712,179 |
$1,269,664 |
47% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Measles (NVS) |
$1,247,229 |
$1,247,229 |
$1,226,993 |
98% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Measles-Rubella (NVS) |
$6,000,965 |
$6,000,965 |
$6,000,965 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Meningitis A (NVS) |
$1,548,371 |
$2,078,871 |
$1,626,072 |
105% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Meningitis A - mini catch-up campaign (NVS) |
$3,134,671 |
$3,134,671 |
$3,134,671 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Meningitis A - mini catch-up op.costs (OPC) |
$2,571,802 |
$2,571,802 |
$2,571,802 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| MR - Operational costs (OPC) |
$4,925,847 |
$4,925,847 |
$4,925,847 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Penta (NVS) |
$65,397,939 |
$66,689,939 |
$65,207,825 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Pneumo (NVS) |
$63,045,663 |
$70,665,663 |
$70,397,044 |
112% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Product Switch Grant (PSG) |
$392,320 |
$392,320 |
$194,285 |
50% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Rotavirus (NVS) |
$42,873,232 |
$46,383,232 |
$38,991,216 |
91% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Vaccine Introduction Grant (VIG) |
$3,558,494 |
$3,558,494 |
$3,558,494 |
100% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Red line on table indicates duration of support based on commitments.
Commitments: Multi-year programme budgets endorsed in principle by the Gavi Board. These become financial commitments upon approval each year for the following calendar year.
Approvals: Total Approved for funding
Download data for commitments, approvals & disbursements in XLS format